| | 56124-62-0 Basic information More.. |
| Product Name: | Valrubicin | | Synonyms: | ad32;antibioticad32;nsc-246131;n-trifluoroacetyladriamycin-14-valerate;n-trifluoroacetyladriamycin14-valerate;n-trifluoroacetyldoxorubicin14-valerate;trifluoroacetyl-adriamyci14-valerate;trifluoroacetyladriamycin-14-valerate | | CAS: | 56124-62-0 | | MF: | C34H36F3NO13 | | MW: | 723.64 | | EINECS: | 680-664-1 | | Mol File: | 56124-62-0.mol |  |
Use
Valrubicin was launched as a new 'chemotherapeutic agent for the
treatment of bladder cancer, particularly in patients with BCG-refractory
carcinoma in situ (CIS) of the bladder for whom immediate cystectomy is
unacceptable. It belongs to the class of anthracyclines, the widest used in
human cancers, and is a N-trifluoroacetyl 14-valerate derivative of doxorubicin.Valrubicin can be obtained in 3 steps from daunomycin by N-trifluoroacetylation
of the sugar moiety then iodination of the 2-acetyl group and introduction of a
valerate residue. A proposed mechanism involved in the cytotoxicity of
Valrubicin coud be the blockade of SV40 large T antigen helicase; this cellular
enzyme is involved in the formation of a ternary complex with DNA to maintain
the topographic structure of DNA during transcription. In patients with CIS of
bladder refractory to front line and second line therapies, intravesical instillation
of Valrubicin resulted in a complete response with a significant rate and allowed
a delay in cystectomy. Systemic absorption was minimal and accordingly
produced a lower incidence of cardiotoxicity compared with doxorubicin.
- Valrubicin
-
- US $39.00-143.00 / mg
- 2025-07-15
- CAS:56124-62-0
- Min. Order:
- Purity: 97.41%
- Supply Ability: 10g
- Valrubicin
-
- US $1990.00 / g
- 2024-02-02
- CAS:56124-62-0
- Min. Order: 1g
- Purity: 98
- Supply Ability: 5 Kg
- Valrubicin
-
- US $15.00-10.00 / KG
- 2021-07-13
- CAS:56124-62-0
- Min. Order: 1KG
- Purity: 99%+ HPLC
- Supply Ability: Monthly supply of 1 ton
|
|
56124-62-0
Recommend Suppliers |
|